239 related articles for article (PubMed ID: 31704847)
1. The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.
Månsson C; Nilsson A; Urdzik J; Karlson BM
Anticancer Res; 2019 Nov; 39(11):6193-6196. PubMed ID: 31704847
[TBL] [Abstract][Full Text] [Related]
2. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
3. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
4. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
6. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
9. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
10. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
11. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients.
Kluger MD; Epelboym I; Schrope BA; Mahendraraj K; Hecht EM; Susman J; Weintraub JL; Chabot JA
Ann Surg Oncol; 2016 May; 23(5):1736-43. PubMed ID: 26714959
[TBL] [Abstract][Full Text] [Related]
12. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
[TBL] [Abstract][Full Text] [Related]
14. Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma.
Xu HX; Li S; Wu CT; Qi ZH; Wang WQ; Jin W; Gao HL; Zhang SR; Xu JZ; Liu C; Long J; Xu J; Ni QX; Yu XJ; Liu L
Pancreatology; 2018 Sep; 18(6):671-677. PubMed ID: 30153903
[TBL] [Abstract][Full Text] [Related]
15. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
16. A Single-institution Experience with Open Irreversible Electroporation for Locally Advanced Pancreatic Carcinoma.
Yan L; Chen YL; Su M; Liu T; Xu K; Liang F; Gu WQ; Lu SC
Chin Med J (Engl); 2016 Dec; 129(24):2920-2925. PubMed ID: 27958223
[TBL] [Abstract][Full Text] [Related]
17. CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection.
Li J; Li Z; Kan H; Sun Z; Xing J; Cheng Y; Bai C
Pancreatology; 2019 Mar; 19(2):302-306. PubMed ID: 30737189
[TBL] [Abstract][Full Text] [Related]
18. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer.
Pan Q; Hu C; Fan Y; Wang Y; Li R; Hu X
J BUON; 2020; 25(3):1643-1649. PubMed ID: 32862617
[TBL] [Abstract][Full Text] [Related]
20. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
